Today our CEO Ali Stunt traveled up to Scotland to join forces with David Park from Pancreatic Cancer UK, and Dr Euan Dickson from Pancreatic Cancer Scotland, at a Scottish Medicines Consortium (SMC) Patient and Clinician Engagement (PACE) meeting. At this meeting, we have requested that SMC reconsider their decision to not provide Scottish patients with access to the advanced pancreatic cancer drug, Abraxane, via NHS Scotland. The SMC are expected to make a decision about this in early January.
The main purpose of PACE is to gather detailed information which will allow a discussion on the benefits of a medicine, including how it can impact the quality of a patient’s life. We have welcomed this movement by the SMC as information may not always be fully captured within the conventional assessment process.
We were extremely disappointed when earlier this year the SMC disapproved Abraxane. Read more about this here: https://pancreaticcanceraction.org/news/pancreatic-cancer-patients-lose-abraxane-turned-smc/